|
|
|
| Effects of PCSK9 Inhibitor-Evolocumab on Blood Lipid Profiles and Vascular Endothelial Function in Patients with Acute Coronary Syndrome |
| LIN Zhihai, WANG Zhengdong, LI Ping, et al |
| The First People's Hospital of Yulin, Guangxi Yulin 537000, China |
|
|
|
|
Abstract Objective: To explore the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor-evolocumab on blood lipid profiles and vascular endothelial function in patients with acute coronary syndrome (ACS). Methods: A total of 160 ACS patients in the hospital from June 2019 to June 2020 were enrolled and divided into observation group and control group by random number table method,80 cases in each group. The control group was given oral atorvastatin,while observation group was given subcutaneous injection of evolocumab on basis of control group. The levels of blood lipid profiles,vascular endothelial function,inflammatory factors and adverse reactions were compared between the two groups. Results: The difference values of cholesterol (TC),triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) before and after treatment in observation group were greater than those in control group (P<0.05),and difference values of serum endothelin 1 (ET-1) and nitric oxide (NO) before and after treatment were greater than those in control group (P<0.05). The difference values of serum inflammatory factors such as tumor necrosis factor α (TNF-α),interleukin 6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) before and after treatment in observation group were greater than those in control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: PCSK9 inhibitor-evolocumab can effectively regulate blood lipid level of ACS patients,improve vascular endothelial function and inhibit inflammation reactions,with high medication safety.
|
|
|
|
|
|
[1] Limbruno U,Goette A,Caterina R D.Commentary:temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation[J]. International Journal of Cardiology,2020,34(8):318~320.
[2] Shiraishi J,Matsubara Y,Hyogo M,et al.Stent-less percutaneous coronary intervention using rotational atherectomy to the noncalcified occlusive lesion with recanalized thrombus[J]. Coronary Artery Disease,2020,13(7):205~207.
[3] Timothy L A,Liuqing W,Jun X,et al.Small molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors:hit to lead optimization of systemic agents.[J]. Journal of Medicinal Chemistry,2018,61(13):67~71.
[4] Baragetti A,Grejtakova D,Casula M,et al.Proprotein convertase subtilisin-kexin type-9 (PCSK9) andtriglyceride-rich lipoprotein metabolism:facts and gaps[J]. Pharmacological Research,2018,130(7):1~11.
[5] Pel P,Chae H S,Nhoek P,et al.A stilbene dimer and flavonoids from the aerial parts of chromolaena odorata with proprotein convertase subtilisin/Kexin type 9 expression inhibitory activity[J]. Bioorganic Chemistry,2020,99(10):384~387.
[6] 颜红兵,唐熠达,杨艳敏急性冠状动脉综合征治疗指南:欧洲心脏病学会:2012年[M].北京:中国环境科学出版社,2012.1~2.
[7] 石清,李俊,程康,等.瑞舒伐他汀短期强化治疗对急性冠状动脉综合征PCI术后患者心功能及炎性反应的影响[J].河北医药,2018,40(13):53~56.
[8] Eleni,Tiniakou,Erika,et al.Use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in statin-associated immune mediated necrotizing myopathy:a case-series.[J]. Arthritis & Rheumatology,2019,71(10):1723~1726.
[9] Su Z L,Hang P Z,Hu J,et al.Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats[J]. Acta Pharmacologica Sinica,2020,44(8):1085~1092.
[10] Ogata A,Oho K,Matsumoto N,et al.Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab[J]. Acta Neurochirurgica,2019,161(11):567~600.
[11] 崔丽,李广平.新型降脂药PCSK9抑制剂的临床研究进展[J].天津医药,2018,46(7):99~104.
[12] 王梅,郭彦青,陈萌萌,等.冠心病患者体内前蛋白转化酶枯草溶菌素9水平与炎性因子的相关性分析[J].心肺血管病杂志,2017,31(4):396~398.
[13] 陈文文,李振山,刘妍妍,等.PCSK9抑制剂依洛尤单抗在降低心血管事件风险中的研究进展[J].中国医院药学杂志,2020,40(3):344~348. |
|
|
|
2021, Vol. 27 
